分组1 - Keros Therapeutics reported quarterly earnings of $3.62 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.01 per share, and showing an improvement from a loss of $1.21 per share a year ago, resulting in an earnings surprise of 36,300% [1] - The company posted revenues of $211.25 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 149.64%, compared to revenues of $0.08 million in the same quarter last year [2] - Keros Therapeutics shares have declined approximately 8.1% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$1.02 on revenues of $8.28 million, and for the current fiscal year, it is -$3.46 on revenues of $100.68 million [7] - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 _______________________________________ ...

Exhibit 99.1 About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissu ...

Keros Therapeutics’ (KROS) shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, including a potential sale of the business. To aid the decision process, KROS will seek guidance from outside financial and legal advisors.As part of the strategic decision, Keros’ board of directors established a Strategic Committee, composed of independent and impartial directors, to oversee the process and provide a recommendation. The move could entail a potential business combinati ...

Keros Therapeutics, Inc.‘s KROS board of directors initiated a formal review process on Thursday to evaluate strategic alternatives, including a sale.“Consistent with our commitment to taking action to enhance stockholder value, Keros’ board determined to undertake a review of all strategic alternatives available to the Company,” said Jean-Jacques Bienaimé, Lead Independent Director. “During the pendency of the strategic review process, we remain focused on the execution of our strategy.”Keros intends to pr ...

Core Viewpoint - Keros Therapeutics, Inc. has initiated a formal review process to evaluate strategic alternatives aimed at maximizing stockholder value, including potential sale or business combination, continued investment in its pipeline, or returning excess capital to stockholders [1][2] Strategic Review Process - The Board of Directors has formed a Strategic Committee to oversee the review process, which will consider a comprehensive range of strategic alternatives [1] - There is no set deadline for the completion of the review process, and Keros plans to provide a preliminary update within 60 days of the announcement [2] Adoption of Stockholder Rights Plan - Keros has adopted a limited-duration stockholder rights plan to protect the integrity of the strategic review process, responding to significant stock accumulations by investors [3][4] - The rights plan aims to ensure fair participation in the review process and to prevent any entity from gaining control without paying an appropriate control premium [4] Rights Plan Details - The rights plan includes a dividend of one preferred share purchase right for each outstanding share of common stock, effective April 24, 2025, with rights becoming exercisable if ownership exceeds 10% [6] - Rights will allow holders to purchase additional shares at twice the market value if triggered, while existing stockholders at or above the threshold are grandfathered [6] - The rights will expire on April 9, 2026, unless redeemed or exchanged earlier by Keros [7] Company Overview - Keros Therapeutics is focused on developing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins, with product candidates targeting pulmonary arterial hypertension, neuromuscular diseases, and cytopenias [9]

LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. Topline results from this ongoing tria ...

Core Viewpoint - Keros Therapeutics, Inc. (KROS) has seen a 3.7% increase in share price over the past four weeks, closing at $11.44, with analysts suggesting a potential upside of 157% based on a mean price target of $29.40 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $10.46, indicating variability among analysts; the lowest estimate suggests a 31.1% increase, while the highest predicts a 275.9% surge to $43 [2] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [7] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about KROS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has risen by 30.5% over the past month, with seven estimates increasing and no negative revisions [10] - KROS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] Caution on Price Targets - While price targets are often sought after by investors, they can mislead; empirical research shows that they rarely indicate actual stock price movements [5][6] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [8]

Keros Therapeutics, Inc. (KROS) closed the last trading session at $11.59, gaining 5.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.40 indicates a 153.7% upside potential.The average comprises 10 short-term price targets ranging from a low of $15 to a high of $43, with a standard deviation of $10.46. While the lowest estimate indicates an increase of 29.4% from the current ...

Financial Performance - Keros Therapeutics reported a quarterly loss of $1.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.93, representing an earnings surprise of -22.58% [1] - The company posted revenues of $3.04 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 97.11%, compared to revenues of $0.14 million in the same quarter last year [2] - Over the last four quarters, Keros Therapeutics has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during this period [2] Stock Performance - Keros Therapeutics shares have declined approximately 31.1% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.33 on revenues of $0.1 million, while for the current fiscal year, it is -$4.87 on revenues of $90.68 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Keros Therapeutics' stock performance [5][6]